Format

Send to

Choose Destination
J Interferon Cytokine Res. 2019 Apr;39(4):205-213. doi: 10.1089/jir.2018.0028. Epub 2019 Mar 11.

Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C.

Author information

1
1 Department of Internal Medicine, Chang Gung Memorial Hospital, Yunlin, Taiwan.
2
2 Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Yunlin, Taiwan.
3
3 Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.
4
4 Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan.
5
5 Division of Thoracic Medicine, Chang Gung Memorial Hospital, Yunlin, Taiwan.
6
6 College of Nursing, Chang Gung University of Science and Technology, Putz City, Chiayi County, Taiwan.

Abstract

This study compares treatment completion rates and outcomes in hepatitis C virus (HCV) patients between those aged <60 and ≥60 years receiving pegylated interferon (PEG-IFN) α-2a or α-2b combined with ribavirin. No significant differences were found in treatment completion rates and virological responses between age-stratified patients or between genotype-stratified patients receiving PEG-IFN α-2a versus PEG-IFN α-2b. Significantly more patients ≥60 years of receiving PEG-IFN α-2b exhibited an early virological response compared to those receiving PEG-IFN α-2a (P = 0.002); for patients <60 years of age, treatment outcomes were similar between the 2 groups. More liver fibrosis was observed in patients with HCV of genotype 1 than in those with genotypes 2 or 3. Mean changes in pre- and post-treatment fibrosis variables (bilirubin, platelet count, liver enzymes, FIB-4, and APRI) in HCV genotype 1 patients were greater in those receiving PEG-IFN α-2b than in those receiving PEG-IFN α-2a. Significant differences were not observed between age- and HCV genotype-stratified patients receiving PEG-IFN α-2a and -α-2b, but α-2b appears to have a modest efficacy advantage over α-2b, particularly in male HCV patients ≥60 years of age.

KEYWORDS:

compliance; efficacy; genotype; hepatitis C virus; liver fibrosis; pegylated interferon

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center